TARSUS PHARMACEUTICALS INC (TARS)
US87650L1035 - Common Stock
Commit To Buy Tarsus Pharmaceuticals At $15, Earn 7.6% Annualized Using Options
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Investors Grab TARS Even Cheaper Than Its Secondary Stock Offering
Tarsus to Participate at Upcoming Investor Conferences
Tarsus to Participate at Upcoming Investor Conferences
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease ...
Tarsus Pharmaceuticals stock dips after pricing $100M securities offering (NASDAQ:TARS)
Tarsus Pharmaceuticals faces a 10% premarket drop as it prices a $100M securities offering, consisting of shares and pre-funded warrants.
Tarsus Announces Pricing of $100.0 Million Public Offering
Tarsus Announces Pricing of $100.0 Million Public Offering
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on...
Tarsus announces proposed $100M public offering (NASDAQ:TARS)
Tarsus Pharmaceuticals initiates a $100 million public offering of its common stock or pre-funded warrants for the purchase of common stock.
Tarsus Pharmaceuticals files for automatic mixed securities shelf (NASDAQ:TARS)
TARS files prospectus for mixed securities shelf, signaling potential fundraising activities.
Tarsus Announces Proposed $100.0 Million Public Offering
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on...
Tarsus Pharmaceuticals GAAP EPS of -$1.31 beats by $0.01, revenue of $13.08M beats by $7.16M (NASDAQ:TARS)
Tarsus Pharmaceuticals reports strong Q4 financial results beating expectations.
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1...
Tarsus reports positive Phase 2 results for Lyme disease product (NASDAQ:TARS)
Tarsus Pharmaceuticals (TARS) reported positive topline results from a Phase 2 proof-of-concept study of its product TP-05 in the prevention of Lyme disease.
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis...
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing,...
Commit To Purchase Tarsus Pharmaceuticals At $15, Earn 42.2% Annualized Using Options
Goldman starts Tarsus at neutral, says Xdemvy launch faces headwinds (NASDAQ:TARS)
Goldman Sachs has initiated coverage of Tarsus Pharmaceuticals (TARS) with a neutral rating, stating that it was taking a "wait and see” approach on the launch
Tarsus files to sell $300M mixed securities shelf (NASDAQ:TARS)
Taurus Pharmaceuticals files a $300M mixed securities shelf prospectus, but it is not an offer to sell.